Overview of Breast Cancer Therapy

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to PET Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hortobagyi G.N.
        • Buzdar A.U.
        Management of locally advanced breast cancer.
        Am J Clin Oncol. 1988; 11: 597-601
        • Fisher B.
        • Anderson S.
        • Bryant J.
        • et al.
        Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer.
        N Engl J Med. 2002; 347: 1233-1241
        • Veronesi U.
        • Cascinelli N.
        • Mariani L.
        • et al.
        Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer.
        N Engl J Med. 2002; 347: 1227-1232
        • Poggi M.M.
        • Danforth D.N.
        • Sciuto L.C.
        • et al.
        Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute Randomized Trial.
        Cancer. 2003; 98: 697-702
        • Voogd A.C.
        • Nielsen M.
        • Peterse J.L.
        • et al.
        Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials.
        J Clin Oncol. 2001; 19: 1688-1697
        • Darby S.
        • McGale P.
        • Correa C.
        • et al.
        Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials.
        Lancet. 2011; 378: 1707-1716
        • van Dongen J.A.
        • Voogd A.C.
        • Fentiman I.S.
        • et al.
        Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial.
        J Natl Cancer Inst. 2000; 92: 1143-1150
        • Wapnir I.L.
        • Anderson S.J.
        • Mamounas E.P.
        • et al.
        Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials.
        J Clin Oncol. 2006; 24: 2028-2037
        • Anderson S.J.
        • Wapnir I.
        • Dignam J.J.
        • et al.
        Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer.
        J Clin Oncol. 2009; 27: 2466-2473
        • Clarke M.
        • Collins R.
        • Darby S.
        • et al.
        Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials.
        Lancet. 2005; 366: 2087-2106
        • Voduc K.D.
        • Cheang M.C.
        • Tyldesley S.
        • et al.
        Breast cancer subtypes and the risk of local and regional relapse.
        J Clin Oncol. 2010; 28: 1684-1691
        • Lowery A.J.
        • Kell M.R.
        • Glynn R.W.
        • et al.
        Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype.
        Breast Cancer Res Treat. 2012; 133: 831-841
      1. National Comprehensive Cancer Network (NCCN). Clinical practice guidelines oncology - breast cancer (Version 2.2017). 2017. Available at: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed July 24, 2017.

        • Moran M.S.
        • Schnitt S.J.
        • Giuliano A.E.
        • et al.
        Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer.
        J Clin Oncol. 2014; 32: 1507-1515
        • Houssami N.
        • Macaskill P.
        • Marinovich M.L.
        • et al.
        The association of surgical margins and local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy: a meta-analysis.
        Ann Surg Oncol. 2014; 21: 717-730
        • Kuchenbaecker K.B.
        • Hopper J.L.
        • Barnes D.R.
        • et al.
        Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.
        JAMA. 2017; 317: 2402-2416
        • Morrow M.
        • Jagsi R.
        • Alderman A.K.
        • et al.
        Surgeon recommendations and receipt of mastectomy for treatment of breast cancer.
        JAMA. 2009; 302: 1551-1556
        • Houssami N.
        • Ciatto S.
        • Macaskill P.
        • et al.
        Accuracy and surgical impact of magnetic resonance imaging in breast cancer staging: systematic review and meta-analysis in detection of multifocal and multicentric cancer.
        J Clin Oncol. 2008; 26: 3248-3258
        • Katipamula R.
        • Degnim A.C.
        • Hoskin T.
        • et al.
        Trends in mastectomy rates at the Mayo Clinic Rochester: effect of surgical year and preoperative magnetic resonance imaging.
        J Clin Oncol. 2009; 27: 4082-4088
        • King T.A.
        • Sakr R.
        • Patil S.
        • et al.
        Clinical management factors contribute to the decision for contralateral prophylactic mastectomy.
        J Clin Oncol. 2011; 29: 2158-2164
        • Sorbero M.E.
        • Dick A.W.
        • Beckjord E.B.
        • et al.
        Diagnostic breast magnetic resonance imaging and contralateral prophylactic mastectomy.
        Ann Surg Oncol. 2009; 16: 1597-1605
        • Fancellu A.
        • Soro D.
        • Castiglia P.
        • et al.
        Usefulness of magnetic resonance in patients with invasive cancer eligible for breast conservation: a comparative study.
        Clin Breast Cancer. 2014; 14: 114-121
        • Pilewskie M.
        • King T.A.
        Magnetic resonance imaging in patients with newly diagnosed breast cancer: a review of the literature.
        Cancer. 2014; 120: 2080-2089
        • Houssami N.
        • Turner R.
        • Macaskill P.
        • et al.
        An individual person data meta-analysis of preoperative magnetic resonance imaging and breast cancer recurrence.
        J Clin Oncol. 2014; 32: 392-401
        • Turnbull L.
        • Brown S.
        • Harvey I.
        • et al.
        Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomised controlled trial.
        Lancet. 2010; 375: 563-571
        • Peters N.H.
        • van Esser S.
        • van den Bosch M.A.
        • et al.
        Preoperative MRI and surgical management in patients with nonpalpable breast cancer: the MONET - randomised controlled trial.
        Eur J Cancer. 2011; 47: 879-886
        • Houssami N.
        • Turner R.M.
        • Morrow M.
        Meta-analysis of pre-operative magnetic resonance imaging (MRI) and surgical treatment for breast cancer.
        Breast Cancer Res Treat. 2017; 165: 273-283
        • Chen A.M.
        • Obedian E.
        • Haffty B.G.
        Breast-conserving therapy in the setting of collagen vascular disease.
        Cancer J. 2001; 7: 480-491
        • Phan C.
        • Mindrum M.
        • Silverman C.
        • et al.
        Matched-control retrospective study of the acute and late complications in patients with collagen vascular diseases treated with radiation therapy.
        Cancer J. 2003; 9: 461-466
        • Lin A.
        • Abu-Isa E.
        • Griffith K.A.
        • et al.
        Toxicity of radiotherapy in patients with collagen vascular disease.
        Cancer. 2008; 113: 648-653
        • Holland R.
        • Veling S.H.
        • Mravunac M.
        • et al.
        Histologic multifocality of Tis, T1-2 breast carcinomas. Implications for clinical trials of breast-conserving surgery.
        Cancer. 1985; 56: 979-990
        • Hopwood P.
        • Haviland J.S.
        • Sumo G.
        • et al.
        Comparison of patient-reported breast, arm, and shoulder symptoms and body image after radiotherapy for early breast cancer: 5-year follow-up in the randomised Standardisation of Breast Radiotherapy (START) trials.
        Lancet Oncol. 2010; 11: 231-240
        • Haviland J.S.
        • Owen J.R.
        • Dewar J.A.
        • et al.
        The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials.
        Lancet Oncol. 2013; 14: 1086-1094
        • Whelan T.J.
        • Pignol J.P.
        • Levine M.N.
        • et al.
        Long-term results of hypofractionated radiation therapy for breast cancer.
        N Engl J Med. 2010; 362: 513-520
        • Hughes K.S.
        • Schnaper L.A.
        • Bellon J.R.
        • et al.
        Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343.
        J Clin Oncol. 2013; 31: 2382-2387
        • Kunkler I.H.
        • Williams L.J.
        • Jack W.J.
        • et al.
        Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial.
        Lancet Oncol. 2015; 16: 266-273
        • Engel J.
        • Kerr J.
        • Schlesinger-Raab A.
        • et al.
        Quality of life following breast-conserving therapy or mastectomy: results of a 5-year prospective study.
        Breast J. 2004; 10: 223-231
        • Hartl K.
        • Janni W.
        • Kastner R.
        • et al.
        Impact of medical and demographic factors on long-term quality of life and body image of breast cancer patients.
        Ann Oncol. 2003; 14: 1064-1071
        • Arndt V.
        • Stegmaier C.
        • Ziegler H.
        • et al.
        Quality of life over 5 years in women with breast cancer after breast-conserving therapy versus mastectomy: a population-based study.
        J Cancer Res Clin Oncol. 2008; 134: 1311-1318
        • Jagsi R.
        • Li Y.
        • Morrow M.
        • et al.
        Patient-reported quality of life and satisfaction with cosmetic outcomes after breast conservation and mastectomy with and without reconstruction: results of a survey of breast cancer survivors.
        Ann Surg. 2015; 261: 1198-1206
        • Bulstrode N.W.
        • Shrotria S.
        Prediction of cosmetic outcome following conservative breast surgery using breast volume measurements.
        Breast. 2001; 10: 124-126
        • Tenofsky P.L.
        • Dowell P.
        • Topalovski T.
        • et al.
        Surgical, oncologic, and cosmetic differences between oncoplastic and nononcoplastic breast conserving surgery in breast cancer patients.
        Am J Surg. 2014; 207: 398-402
        • Rietjens M.
        • Urban C.A.
        • Rey P.C.
        • et al.
        Long-term oncological results of breast conservative treatment with oncoplastic surgery.
        Breast. 2007; 16: 387-395
        • Meretoja T.J.
        • Rasia S.
        • von Smitten K.A.
        • et al.
        Late results of skin-sparing mastectomy followed by immediate breast reconstruction.
        Br J Surg. 2007; 94: 1220-1225
        • Medina-Franco H.
        • Vasconez L.O.
        • Fix R.J.
        • et al.
        Factors associated with local recurrence after skin-sparing mastectomy and immediate breast reconstruction for invasive breast cancer.
        Ann Surg. 2002; 235: 814-819
        • Carlson G.W.
        • Styblo T.M.
        • Lyles R.H.
        • et al.
        The use of skin sparing mastectomy in the treatment of breast cancer: the Emory experience.
        Surg Oncol. 2003; 12: 265-269
        • Lanitis S.
        • Tekkis P.P.
        • Sgourakis G.
        • et al.
        Comparison of skin-sparing mastectomy versus non-skin-sparing mastectomy for breast cancer: a meta-analysis of observational studies.
        Ann Surg. 2010; 251: 632-639
        • Smith B.L.
        • Tang R.
        • Rai U.
        • et al.
        Oncologic safety of nipple-sparing mastectomy in women with breast cancer.
        J Am Coll Surg. 2017; 225: 361-365
        • Moo T.A.
        • Pinchinat T.
        • Mays S.
        • et al.
        Oncologic outcomes after nipple-sparing mastectomy.
        Ann Surg Oncol. 2016; 23: 3221-3225
        • de Alcantara Filho P.
        • Capko D.
        • Barry J.M.
        • et al.
        Nipple-sparing mastectomy for breast cancer and risk-reducing surgery: the Memorial Sloan-Kettering Cancer Center experience.
        Ann Surg Oncol. 2011; 18: 3117-3122
        • Orzalesi L.
        • Casella D.
        • Santi C.
        • et al.
        Nipple sparing mastectomy: surgical and oncological outcomes from a national multicentric registry with 913 patients (1006 cases) over a six year period.
        Breast. 2016; 25: 75-81
        • Recht A.
        • Gray R.
        • Davidson N.E.
        • et al.
        Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group.
        J Clin Oncol. 1999; 17: 1689-1700
        • Overgaard M.
        • Jensen M.B.
        • Overgaard J.
        • et al.
        Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial.
        Lancet. 1999; 353: 1641-1648
        • Recht A.
        • Edge S.B.
        • Solin L.J.
        • et al.
        Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology.
        J Clin Oncol. 2001; 19: 1539-1569
        • Moo T.A.
        • McMillan R.
        • Lee M.
        • et al.
        Selection criteria for postmastectomy radiotherapy in t1-t2 tumors with 1 to 3 positive lymph nodes.
        Ann Surg Oncol. 2013; 20: 3169-3174
        • Sharma R.
        • Bedrosian I.
        • Lucci A.
        • et al.
        Present-day locoregional control in patients with t1 or t2 breast cancer with 0 and 1 to 3 positive lymph nodes after mastectomy without radiotherapy.
        Ann Surg Oncol. 2010; 17: 2899-2908
        • McGale P.
        • Taylor C.
        • Correa C.
        • et al.
        • EBCTCG (Early Breast Cancer Trialists' Collaborative Group)
        Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials.
        Lancet. 2014; 383: 2127-2135
        • Recht A.
        • Comen E.A.
        • Fine R.E.
        • et al.
        Postmastectomy radiotherapy: an American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of surgical oncology focused guideline update.
        J Clin Oncol. 2016; 34: 4431-4442
        • Hoffman K.E.
        • Mittendorf E.A.
        • Buchholz T.A.
        Optimising radiation treatment decisions for patients who receive neoadjuvant chemotherapy and mastectomy.
        Lancet Oncol. 2012; 13: e270-e276
        • McCartan D.
        • Stempel M.
        • Eaton A.
        • et al.
        Impact of body mass index on clinical axillary nodal assessment in breast cancer patients.
        Ann Surg Oncol. 2016; 23: 3324-3329
        • Kern K.A.
        Concordance and validation study of sentinel lymph node biopsy for breast cancer using subareolar injection of blue dye and technetium 99m sulfur colloid.
        J Am Coll Surg. 2002; 195: 467-475
        • Kern K.A.
        Sentinel lymph node mapping in breast cancer using subareolar injection of blue dye.
        J Am Coll Surg. 1999; 189: 539-545
        • Mertz L.
        • Mathelin C.
        • Marin C.
        • et al.
        Subareolar injection of 99m-Tc sulfur colloid for sentinel nodes identification in multifocal invasive breast cancer.
        Bull Cancer. 1999; 86 ([in French]): 939-945
        • Boolbol S.K.
        • Fey J.V.
        • Borgen P.I.
        • et al.
        Intradermal isotope injection: a highly accurate method of lymphatic mapping in breast carcinoma.
        Ann Surg Oncol. 2001; 8: 20-24
        • Krag D.
        • Weaver D.
        • Ashikaga T.
        • et al.
        The sentinel node in breast cancer–a multicenter validation study.
        N Engl J Med. 1998; 339: 941-946
        • Veronesi U.
        • Viale G.
        • Paganelli G.
        • et al.
        Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study.
        Ann Surg. 2010; 251: 595-600
        • Van Zee K.J.
        • Manasseh D.M.
        • Bevilacqua J.L.
        • et al.
        A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy.
        Ann Surg Oncol. 2003; 10: 1140-1151
        • Weiser M.R.
        • Montgomery L.L.
        • Tan L.K.
        • et al.
        Lymphovascular invasion enhances the prediction of non-sentinel node metastases in breast cancer patients with positive sentinel nodes.
        Ann Surg Oncol. 2001; 8: 145-149
        • Hwang R.F.
        • Krishnamurthy S.
        • Hunt K.K.
        • et al.
        Clinicopathologic factors predicting involvement of nonsentinel axillary nodes in women with breast cancer.
        Ann Surg Oncol. 2003; 10: 248-254
        • Giuliano A.E.
        • Hunt K.K.
        • Ballman K.V.
        • et al.
        Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial.
        JAMA. 2011; 305: 569-575
        • Giuliano A.E.
        • Ballman K.
        • McCall L.
        • et al.
        Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: long-term follow-up from the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial.
        Ann Surg. 2016; 264: 413-420
        • Giuliano A.E.
        • Ballman K.V.
        • McCall L.
        • et al.
        Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) Randomized Clinical Trial.
        JAMA. 2017; 318: 918-926
        • Dengel L.T.
        • Van Zee K.J.
        • King T.A.
        • et al.
        Axillary dissection can be avoided in the majority of clinically node-negative patients undergoing breast-conserving therapy.
        Ann Surg Oncol. 2014; 21: 22-27
        • Donker M.
        • Slaets L.
        • van Tienhoven G.
        • et al.
        Axillary lymph node dissection versus axillary radiotherapy in patients with a positive sentinel node: the AMAROS trial.
        Ned Tijdschr Geneeskd. 2015; 159 ([in Dutch]): A9302
        • Morrow M.
        • Van Zee K.J.
        • Patil S.
        • et al.
        Axillary dissection and nodal irradiation can be avoided for most node-positive z0011-eligible breast cancers: a prospective validation study of 793 patients.
        Ann Surg. 2017; 266: 457-462
        • Pilewskie M.
        • Jochelson M.
        • Gooch J.C.
        • et al.
        Is preoperative axillary imaging beneficial in identifying clinically node-negative patients requiring axillary lymph node dissection?.
        J Am Coll Surg. 2016; 222: 138-145
        • Pilewskie M.
        • Mautner S.K.
        • Stempel M.
        • et al.
        Does a positive axillary lymph node needle biopsy result predict the need for an axillary lymph node dissection in clinically node-negative breast cancer patients in the ACOSOG Z0011 era?.
        Ann Surg Oncol. 2016; 23: 1123-1128
        • van der Hage J.A.
        • van de Velde C.J.
        • Julien J.P.
        • et al.
        Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902.
        J Clin Oncol. 2001; 19: 4224-4237
        • Broet P.
        • Scholl S.M.
        • de la Rochefordiere A.
        • et al.
        Short and long-term effects on survival in breast cancer patients treated by primary chemotherapy: an updated analysis of a randomized trial.
        Breast Cancer Res Treat. 1999; 58: 151-156
        • Fisher B.
        • Bryant J.
        • Wolmark N.
        • et al.
        Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
        J Clin Oncol. 1998; 16: 2672-2685
        • Mieog J.S.
        • van der Hage J.A.
        • van de Velde C.J.
        Neoadjuvant chemotherapy for operable breast cancer.
        Br J Surg. 2007; 94: 1189-1200
        • Jochelson M.S.
        • Lampen-Sachar K.
        • Gibbons G.
        • et al.
        Do MRI and mammography reliably identify candidates for breast conservation after neoadjuvant chemotherapy?.
        Ann Surg Oncol. 2015; 22: 1490-1495
        • Feliciano Y.
        • Mamtani A.
        • Morrow M.
        • et al.
        Do calcifications seen on mammography after neoadjuvant chemotherapy for breast cancer always need to be excised?.
        Ann Surg Oncol. 2017; 24: 1492-1498
        • Classe J.M.
        • Bordes V.
        • Campion L.
        • et al.
        Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study.
        J Clin Oncol. 2009; 27: 726-732
        • Xing Y.
        • Foy M.
        • Cox D.D.
        • et al.
        Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer.
        Br J Surg. 2006; 93: 539-546
        • Kelly A.M.
        • Dwamena B.
        • Cronin P.
        • et al.
        Breast cancer sentinel node identification and classification after neoadjuvant chemotherapy-systematic review and meta-analysis.
        Acad Radiol. 2009; 16: 551-563
        • Hunt K.K.
        • Yi M.
        • Mittendorf E.A.
        • et al.
        Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients.
        Ann Surg. 2009; 250: 558-566
        • Mamtani A.
        • Barrio A.V.
        • King T.A.
        • et al.
        How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases? Results of a prospective study.
        Ann Surg Oncol. 2016; 23: 3467-3474
        • Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
        Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
        Lancet. 2005; 365: 1687-1717
        • Citron M.L.
        • Berry D.A.
        • Cirrincione C.
        • et al.
        Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.
        J Clin Oncol. 2003; 21: 1431-1439
        • Sparano J.A.
        • Wang M.
        • Martino S.
        • et al.
        Weekly paclitaxel in the adjuvant treatment of breast cancer.
        N Engl J Med. 2008; 358: 1663-1671
        • Sparano J.A.
        • Zhao F.
        • Martino S.
        • et al.
        Long-term follow-up of the E1199 phase III trial evaluating the role of taxane and schedule in operable breast cancer.
        J Clin Oncol. 2015; 33: 2353-2360
        • Swain S.M.
        • Tang G.
        • Geyer Jr., C.E.
        • et al.
        Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.
        J Clin Oncol. 2013; 31: 3197-3204
        • Peto R.
        • Davies C.
        • Godwin J.
        • et al.
        • Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
        Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.
        Lancet. 2012; 379: 432-444
        • Berry D.A.
        • Cirrincione C.
        • Henderson I.C.
        • et al.
        Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.
        Jama. 2006; 295: 1658-1667
        • Paik S.
        • Tang G.
        • Shak S.
        • et al.
        Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
        J Clin Oncol. 2006; 24: 3726-3734
        • Sparano J.A.
        • Gray R.J.
        • Makower D.F.
        • et al.
        Prospective validation of a 21-gene expression assay in breast cancer.
        N Engl J Med. 2015; 373: 2005-2014
        • Albain K.S.
        • Barlow W.E.
        • Shak S.
        • et al.
        Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
        Lancet Oncol. 2010; 11: 55-65
        • Cameron D.
        • Piccart-Gebhart M.J.
        • Gelber R.D.
        • et al.
        11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.
        Lancet. 2017; 389: 1195-1205
        • Perez E.A.
        • Romond E.H.
        • Suman V.J.
        • et al.
        Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.
        J Clin Oncol. 2014; 32: 3744-3752
        • Piccart-Gebhart M.J.
        • Procter M.
        • Leyland-Jones B.
        • et al.
        Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
        N Engl J Med. 2005; 353: 1659-1672
        • Romond E.H.
        • Perez E.A.
        • Bryant J.
        • et al.
        Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
        N Engl J Med. 2005; 353: 1673-1684
        • Slamon D.
        • Eiermann W.
        • Robert N.
        • et al.
        Adjuvant trastuzumab in HER2-positive breast cancer.
        N Engl J Med. 2011; 365: 1273-1283
      2. Slamon DJ, Eiermann W, Robert NJ, et al. Ten year follow-up of the BCIRG-006 trial comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC®T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC®TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+ early breast cancer patients. San Antonio Breast Cancer Symposium 2015; Abstract No. S5–04. Presented December 11, 2015. Available on Page 999 at: https://www.sabcs.org/Portals/SABCS2016/Documents/SABCS-2015-Abstracts.pdf?v=5. Accessed September 29, 2017.

        • Tolaney S.M.
        • Barry W.T.
        • Dang C.T.
        • et al.
        Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.
        N Engl J Med. 2015; 372: 134-141
        • Gianni L.
        • Pienkowski T.
        • Im Y.H.
        • et al.
        Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
        Lancet Oncol. 2012; 13: 25-32
        • Schneeweiss A.
        • Chia S.
        • Hickish T.
        • et al.
        Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).
        Ann Oncol. 2013; 24: 2278-2284
        • von Minckwitz G.
        • Procter M.
        • de Azambuja E.
        • et al.
        Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer.
        N Engl J Med. 2017; 377: 122-131
        • Davies C.
        • Godwin J.
        • Gray R.
        • et al.
        • Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
        Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.
        Lancet. 2011; 378: 771-784
        • Davies C.
        • Pan H.
        • Godwin J.
        • et al.
        Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
        Lancet. 2013; 381: 805-816
        • Goss P.E.
        • Ingle J.N.
        • Martino S.
        • et al.
        Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
        J Natl Cancer Inst. 2005; 97: 1262-1271
        • Goss P.E.
        • Ingle J.N.
        • Pritchard K.I.
        • et al.
        Extending aromatase-inhibitor adjuvant therapy to 10 years.
        N Engl J Med. 2016; 375: 209-219
        • Burstein H.J.
        • Temin S.
        • Anderson H.
        • et al.
        Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update.
        J Clin Oncol. 2014; 32: 2255-2269
        • Pagani O.
        • Regan M.M.
        • Walley B.A.
        • et al.
        Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.
        N Engl J Med. 2014; 371: 107-118
        • Moore H.C.
        • Unger J.M.
        • Phillips K.A.
        • et al.
        Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.
        N Engl J Med. 2015; 372: 923-932
        • Azim Jr., H.A.
        • Santoro L.
        • Pavlidis N.
        • et al.
        Safety of pregnancy following breast cancer diagnosis: a meta-analysis of 14 studies.
        Eur J Cancer. 2011; 47: 74-83
        • Margolese R.G.
        • Cecchini R.S.
        • Julian T.B.
        • et al.
        Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
        Lancet. 2016; 387: 849-856
        • Visvanathan K.
        • Hurley P.
        • Bantug E.
        • et al.
        Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline.
        J Clin Oncol. 2013; 31: 2942-2962
        • Muss H.B.
        • Berry D.A.
        • Cirrincione C.T.
        • et al.
        Adjuvant chemotherapy in older women with early-stage breast cancer.
        N Engl J Med. 2009; 360: 2055-2065
        • Emens L.A.
        • Davidson N.E.
        The follow-up of breast cancer.
        Semin Oncol. 2003; 30: 338-348
        • Kokko R.
        • Holli K.
        • Hakama M.
        Ca 15-3 in the follow-up of localised breast cancer: a prospective study.
        Eur J Cancer. 2002; 38: 1189-1193
        • Dal Maso L.
        • Zucchetto A.
        • Talamini R.
        • et al.
        Effect of obesity and other lifestyle factors on mortality in women with breast cancer.
        Int J Cancer. 2008; 123: 2188-2194
        • Ballard-Barbash R.
        • Friedenreich C.M.
        • Courneya K.S.
        • et al.
        Physical activity, biomarkers, and disease outcomes in cancer survivors: a systematic review.
        J Natl Cancer Inst. 2012; 104: 815-840
        • Betof A.S.
        • Dewhirst M.W.
        • Jones L.W.
        Effects and potential mechanisms of exercise training on cancer progression: a translational perspective.
        Brain Behav Immun. 2013; 30: S75-S87